Skip to search formSkip to main contentSkip to account menu

Tysabri

National Institutes of Health

Related topics

Related topics

3 relations
15 ML natalizumab 20 MG/ML Injection [Tysabri]natalizumab Injection [Tysabri]

Broader (1)

natalizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
4-Week toxicity study of biosimilar natalizumab in comparison to Tysabri® by repeated intravenous infusion to cynomolgus monkeys
Abstract The objective of the study was to obtain information on the toxicity of biosimilar natalizumab (PB006) in comparison to… 
2019
2019
195 MS disease modifying therapy (DMT) sequencing – tysabri to mavenclad de-escalation in JC-virus positive MS patients
Background There is a significant UK variation in the DMT sequencing strategies for high PML risk patients on Tysabri. In Greater… 
2018
2018
PREGNANCY, NEONATAL AND DISEASE OUTCOMES IN WOMEN WITH RELAPSING REMITTING MULTIPLE SCLEROSIS
2017
2017
A Massive Overdose of Dalfampridine
2016
2016
Bacterial meningitis in a patient with multiple sclerosis receiving Tysabri
The most important adverse effect of natalizumab is progressive multifocal leukoencephalopathy (PML).1 Apart from PML, there are… 
Review
2010
Review
2010
Novartis eyes oral MS drug as potential blockbuster
1135 has shown side effects that include a slowed heart rate, macular edema and breathing and liver problems. Although these may… 
Review
2009
Review
2009
Safety profile of Tysabri: international risk management plan
Therapeutic monoclonal antibodies are potent new tools for a molecular targeted approach to modify the course of multiple… 
2008
2008
Natalizumab (tysabri®) y leucoencefalopatía multifocal progresiva: (Nota informativa de la AEMPS 2008/15, de 14 de Agosto de 2008)
La Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS) ha recibido nueva informacion de seguridad concerniente al… 
2005
2005
Tysabri raises alarm bells on drug class
Although the financial implications of Elan's and Biogen Idec's shock withdrawal from the market of the highly promising multiple… 
2005
2005
Multiple sclerosis woes
Multiple sclerosis woes The multiple sclerosis drug Tysabri showed such efficacy in two Phase III clinical trials over one year… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)